Drug intelligence / Profile preview

Xinjikang No. 0

Development stage: Preclinical
Administration: Oral

Overview

Xinjikang No. 0 (心肌康0号) is a Traditional Chinese Medicine (TCM) formulation. It has been investigated in clinical trials for the treatment of viral myocarditis, specifically for patients presenting with the TCM syndrome of 'heat-toxin invading the heart' (热毒侵心证). As a TCM product, its mechanism of action is typically understood within the framework of traditional Chinese medical theory, which often involves balancing bodily functions and addressing underlying patterns of disharmony, rather than targeting specific molecular pathways as in Western pharmacology.

Other names: 心肌康0号

Beyond the preview

Go deeper on Xinjikang No. 0.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xinjikang No. 0.

Explore the full profile